CA2851658C - Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens - Google Patents

Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens Download PDF

Info

Publication number
CA2851658C
CA2851658C CA2851658A CA2851658A CA2851658C CA 2851658 C CA2851658 C CA 2851658C CA 2851658 A CA2851658 A CA 2851658A CA 2851658 A CA2851658 A CA 2851658A CA 2851658 C CA2851658 C CA 2851658C
Authority
CA
Canada
Prior art keywords
promoter
iltv
vaccine
rmdvnp
rhvt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2851658A
Other languages
English (en)
French (fr)
Other versions
CA2851658A1 (en
Inventor
Stephanie COOK
Mohamad Morsey
Gary Petersen
Paulus Jacobus Antonius Sondermeijer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47046611&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2851658(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intervet International BV filed Critical Intervet International BV
Priority to CA3146727A priority Critical patent/CA3146727C/en
Publication of CA2851658A1 publication Critical patent/CA2851658A1/en
Application granted granted Critical
Publication of CA2851658C publication Critical patent/CA2851658C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2851658A 2011-10-21 2012-10-19 Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens Active CA2851658C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3146727A CA3146727C (en) 2011-10-21 2012-10-19 Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161549844P 2011-10-21 2011-10-21
US61/549,844 2011-10-21
PCT/EP2012/070728 WO2013057236A1 (en) 2011-10-21 2012-10-19 Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3146727A Division CA3146727C (en) 2011-10-21 2012-10-19 Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens

Publications (2)

Publication Number Publication Date
CA2851658A1 CA2851658A1 (en) 2013-04-25
CA2851658C true CA2851658C (en) 2022-03-15

Family

ID=47046611

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2851658A Active CA2851658C (en) 2011-10-21 2012-10-19 Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
CA3146727A Active CA3146727C (en) 2011-10-21 2012-10-19 Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
CA3206983A Pending CA3206983A1 (en) 2011-10-21 2012-10-19 Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA3146727A Active CA3146727C (en) 2011-10-21 2012-10-19 Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
CA3206983A Pending CA3206983A1 (en) 2011-10-21 2012-10-19 Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens

Country Status (19)

Country Link
US (2) US8932604B2 (enExample)
EP (1) EP2768964B1 (enExample)
JP (2) JP6134324B2 (enExample)
CN (2) CN103890183A (enExample)
AR (1) AR088401A1 (enExample)
BR (1) BR112014009565A2 (enExample)
CA (3) CA2851658C (enExample)
ES (1) ES2700243T3 (enExample)
FR (1) FR21C1003I2 (enExample)
HU (2) HUE041723T2 (enExample)
IN (1) IN2014CN02681A (enExample)
MX (1) MX352206B (enExample)
MY (2) MY173856A (enExample)
PH (1) PH12014500793A1 (enExample)
PL (1) PL2768964T3 (enExample)
RU (1) RU2624037C2 (enExample)
SA (1) SA112330950B1 (enExample)
TR (1) TR201818883T4 (enExample)
WO (1) WO2013057236A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015013178A1 (en) * 2013-07-23 2015-01-29 University Of Maryland Infectious laryngotracheitis virus (iltv) vaccine using recombinant newcastle disease virus vector
US10383936B2 (en) * 1999-05-05 2019-08-20 University Of Maryland, College Park Infectious laryngotracheitis virus (ILTV) vaccine using recombinant newcastle disease virus vector
IN2014CN02681A (enExample) 2011-10-21 2015-07-03 Intervet Int Bv
US9101598B2 (en) * 2011-11-30 2015-08-11 Merial, Inc. Recombinant Gallid herpesvirus 3 (MDV serotype 2) vectors expressing antigens of avian pathogens and uses thereof
EP2644702A1 (en) 2012-03-30 2013-10-02 Ceva Sante Animale Multivalent recombinant avian herpes virus and vaccine for immunizing avian species
AR097029A1 (es) 2013-07-26 2016-02-17 Intervet Int Bv Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
EP2845904A1 (en) 2013-09-06 2015-03-11 Ceva Sante Animale Recombinant Marek's disease viruses and uses thereof
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
US9950059B2 (en) 2014-02-25 2018-04-24 The United States Of America, As Represented By The Secretary Of Agriculture. Immunogenic composition
AR103245A1 (es) * 2014-12-24 2017-04-26 Intervet Int Bv Vacuna vectorial basada en hvt (herpes virus de los pavos) frente a nd (enfermedad de newcastle) - ibd (enfermedad de gumboro) mejorada
EP3050572A1 (en) * 2015-01-29 2016-08-03 Ceva Sante Animale Recombinant MDV1 and the uses thereof
EP3268034A4 (en) * 2015-03-05 2018-11-14 Northwestern University Non-neuroinvasive viruses and uses thereof
EP3334833A4 (en) 2015-08-10 2019-04-24 The Texas A&M University System RECOMBINANT TURKEY HERPESVIRUS VACCINES AND USES THEREOF
CN109310750B (zh) 2016-06-17 2022-08-12 英特维特国际股份有限公司 编码传染性喉气管炎病毒和传染性法氏囊病病毒抗原的重组非致病性马立克氏病病毒构建体
RU2752836C2 (ru) * 2016-12-14 2021-08-09 БЁРИНГЕР ИНГЕЛЬХАЙМ ЭНИМАЛ ХЕЛТ ЮЭсЭй ИНК. Рекомбинантные hvt-векторы, экспрессирующие множественные антигены патогенов птиц, и содержащие их вакцины
CN111542599A (zh) * 2017-10-12 2020-08-14 英特维特国际股份有限公司 编码多种异源抗原的重组非致病性马尔克氏病病毒构建体
CN107670032A (zh) * 2017-10-27 2018-02-09 贵州福斯特生物科技有限公司 家禽油乳剂灭活疫苗佐剂及其相应疫苗的制备方法
WO2019121888A1 (en) 2017-12-20 2019-06-27 Intervet International B.V. Improved diluent for cell-associated alphaherpesvirus vaccine
BR112021012032A2 (pt) 2018-12-21 2021-11-16 Ceva Sante Animale Herpesvírus aviários recombinantes contendo múltiplos genes estranhos
CN114616325A (zh) 2019-09-11 2022-06-10 硕腾服务有限责任公司 表达禽病原体抗原的重组火鸡疱疹病毒载体和其用途
WO2021123104A1 (en) 2019-12-20 2021-06-24 Intervet International B.V. Multivalent hvt vector vaccine
CN116457461A (zh) 2020-10-15 2023-07-18 法国诗华动物保健公司 重组hvt及其用途
MX2023007634A (es) 2020-12-24 2023-07-14 Intervet Int Bv Vacuna de vector hvt multivalente.
JP2025515050A (ja) 2022-05-05 2025-05-13 インターベット インターナショナル ベー． フェー． 新規多価ｈｖｔベクターワクチン
WO2025048868A1 (en) * 2023-08-30 2025-03-06 Edge Animal Health, Inc. Use of codon deoptimisation and optimisation to produce a laryngotracheitis virus-attenuated vaccine
TW202540431A (zh) * 2024-03-27 2025-10-16 大陸商勃林格殷格翰動物保健（中國）有限公司 重組血清1型馬立克氏病病毒

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5928648A (en) 1985-09-06 1999-07-27 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US5961982A (en) * 1985-09-06 1999-10-05 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US6121043A (en) 1985-09-06 2000-09-19 Syntro Corporation Recombinant herpesvirus of turkeys comprising a foreign DNA inserted into a non-essential region of the herpesvirus of turkeys genome
US5965138A (en) 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US5834305A (en) 1985-09-06 1998-11-10 Syntro Corporation Attenuated herpesvirus, herpesvirus which include foreign DNA encoding an amino acid sequence and vaccines containing same
AU602875B2 (en) 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
ATE342996T1 (de) 1986-01-27 2006-11-15 Schering Plough Ltd Attenuierte herpesviren, herpesviren die eine aminosäuresequenz kodierende fremde dna enthalten,und diese enthaltende impfstoffe
AU623333B2 (en) 1986-01-27 1992-05-14 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
GB8603341D0 (en) 1986-02-11 1986-03-19 Portapax Ltd Foam sheet
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
DE3854190T2 (de) 1987-07-27 1996-03-28 Syntro Corp Attenuierte herpesviren, herpesviren, die für eine aminosäuresequenz kodierende fremde dns beeinhalten und sie enthaltende impfstoffe.
US5250298A (en) 1988-10-07 1993-10-05 University Of Delaware Live attenuated newcastle disease virus vaccines and preparation thereof
US5919461A (en) * 1989-10-18 1999-07-06 Akzo Nobel N.V. Nonpathogenic infectious bursal disease virus and vaccine
ES2070997T3 (es) 1989-12-04 1995-06-16 Akzo Nobel Nv Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
FR2659349B1 (fr) 1990-03-12 1993-12-24 Rhone Merieux Virus herpes recombinants notamment pour la realisation de vaccins, leur procede de preparation, les plasmides realises au cours de ce procede et les vaccins obtenus.
WO1992003554A1 (en) 1990-08-24 1992-03-05 Arthur Webster Pty. Ltd. Infectious laryngotracheitis virus vaccine
FR2666589B1 (fr) 1990-09-07 1994-08-05 Rhone Merieux Nouveaux virus herpes recombinants, vaccin a base de ces recombinants, leur procede de preparation, genes, vecteurs et plasmides utilises dans ce procede.
US5279965A (en) 1991-04-05 1994-01-18 Keeler Jr Calvin L Recombinant infectious laryngotracheitis virus
US6913751B2 (en) 1992-06-12 2005-07-05 Schering-Plough Veterinary Corporation Recombinant avian herpesvirus useful in vaccine production
US6183753B1 (en) 1994-08-09 2001-02-06 Schering-Plough Veterinary Corp. Recombinant chimeric virus and uses thereof
US5853733A (en) * 1993-02-26 1998-12-29 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US6875856B2 (en) * 1993-09-24 2005-04-05 Syntro Corporation Recombinant infectious laryngotracheitis virus and uses thereof
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
JP3964458B2 (ja) 1995-03-23 2007-08-22 シェリング−プロウ・リミテッド 組換え型伝染性喉頭気管炎ウイルスおよびその使用
EP0837929A2 (en) * 1995-07-07 1998-04-29 Nippon Zeon Co., Ltd. Marek's disease virus genes and their use in vaccines for protection against marek's disease
FR2757061B1 (fr) 1996-12-16 1999-03-26 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
WO1999018215A1 (en) 1997-10-03 1999-04-15 Nippon Zeon Co., Ltd. Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
EP1038952A3 (en) * 1998-12-09 2001-06-27 Pfizer Products Inc. Processes for preparation of Marek's Disease Virus using continuous avian cell lines
US6299882B1 (en) * 1999-04-09 2001-10-09 Schering Corporation UL54.5 of Marek's disease virus (MDV)
EP1178111A1 (en) * 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
US7314715B2 (en) 2001-06-14 2008-01-01 Schering-Plough Animal Health Corporation Recombinant avian herpesvirus useful in vaccine production
US6764684B2 (en) 2001-09-28 2004-07-20 Zeon Corporation Avian herpesvirus-based recombinant infectious bursal disease vaccine
US7029681B2 (en) 2002-03-08 2006-04-18 Schweitzer Chemical Corporation Multiple and multivalent DNA vaccines in ovo
US7862821B2 (en) * 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
CN105567648B (zh) 2009-04-15 2019-09-03 法国诗华大药厂 用于免疫接种水禽物种的重组禽疱疹病毒载体和疫苗
TWI468157B (zh) 2009-04-29 2015-01-11 Intervet Int Bv 形成錠劑的方法，進行該方法的系統及包含該錠劑的包裝物
US8986706B2 (en) 2010-08-31 2015-03-24 Merial, Inc. Newcastle disease virus vectored herpesvirus vaccines
WO2013057235A1 (en) 2011-10-21 2013-04-25 Intervet International B.V. Recombinant nonpathogenic mdv vector providing multivalent immunity
IN2014CN02681A (enExample) * 2011-10-21 2015-07-03 Intervet Int Bv
HRP20190525T4 (hr) 2011-11-30 2023-01-20 Boehringer Ingelheim Animal Health USA Inc. Rekombinantni vektori gallid herpesvirusa 3 (mdv serotip 2) koji eksprimiraju antigene ptičjih patogena i njihove uporabe
EP2845904A1 (en) 2013-09-06 2015-03-11 Ceva Sante Animale Recombinant Marek's disease viruses and uses thereof

Also Published As

Publication number Publication date
EP2768964B1 (en) 2018-10-10
CA3146727C (en) 2023-10-31
JP2015500631A (ja) 2015-01-08
PL2768964T3 (pl) 2019-02-28
MY173856A (en) 2020-02-25
MX352206B (es) 2017-11-13
AR088401A1 (es) 2014-05-28
WO2013057236A1 (en) 2013-04-25
RU2014120471A (ru) 2015-11-27
JP6313874B2 (ja) 2018-04-18
JP2017121250A (ja) 2017-07-13
US20150344528A1 (en) 2015-12-03
TR201818883T4 (tr) 2019-01-21
CN107805631A (zh) 2018-03-16
JP6134324B2 (ja) 2017-05-24
MX2014004739A (es) 2014-08-01
CA2851658A1 (en) 2013-04-25
CN103890183A (zh) 2014-06-25
HUE041723T2 (hu) 2019-05-28
CA3146727A1 (en) 2013-04-25
US20130101619A1 (en) 2013-04-25
PH12014500793A1 (en) 2014-06-30
HUS2100002I1 (hu) 2021-03-01
RU2624037C2 (ru) 2017-06-30
EP2768964A1 (en) 2014-08-27
US9409954B2 (en) 2016-08-09
CN107805631B (zh) 2021-10-01
US8932604B2 (en) 2015-01-13
MY191634A (en) 2022-07-04
FR21C1003I1 (fr) 2021-03-05
BR112014009565A2 (pt) 2017-04-18
FR21C1003I2 (fr) 2024-03-01
IN2014CN02681A (enExample) 2015-07-03
CA3206983A1 (en) 2013-04-25
SA112330950B1 (ar) 2015-08-10
ES2700243T3 (es) 2019-02-14

Similar Documents

Publication Publication Date Title
CA3146727C (en) Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
US12239704B2 (en) Recombinant non-pathogenic Marek's disease virus constructs encoding multiple heterologous antigens
US11730807B2 (en) Multivalent recombinant avian herpes viruses and vaccines for immunizing avian species
US12514922B2 (en) Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens
US20250295753A1 (en) Larygotracheitis Virus (LT) Vector Vaccines for use with Avian Respiratory Pathogens
RU2777400C2 (ru) Рекомбинантные непатогенные конструкции вируса болезни марека, кодирующие антигены вируса инфекционного ларинготрахеита и вируса инфекционного бурсита

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170815

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250908

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250908